OptimizeRx Corp — Director's Dealing 2025

Dec 23, 2025

SEC Form 4/A — Form 4/A

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2025-12-19

Reporting Person: Stelmakh Edward (Chief Finance & Strat Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-19	Common Stock	M	5237	—	Acquired	128218	Direct
2025-12-19	Common Stock	F	1388	$13.51	Disposed	126830	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-19	Restricted Stock Units	$	M	5237	Disposed	2026-12-19	Common Stock (5237)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: This Form 4/A is filed to correct the transaction code in Table I. The disposition of 1,388 shares previously reported as Transaction Code S should have been reported as Transaction Code F to reflect shares withheld by the issuer to satisfy tax withholding obligations.

F3: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.

F4: The restricted stock units vest in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date.